Ares Financial Consulting
PTCT icon

Ares Financial Consulting’s PTC Therapeutics PTCT Stock Holding History

Ares Financial Consulting’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-34
Closed -$2.77K – 1120
2026
Q2 		$2.77K Buy
+34
New +$2.46K ﹤0.01% 836

Other funds holding PTCT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Ares Financial Consulting's PTCT Position: Q3 2026 in Review

Ares Financial Consulting sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 34 shares — an estimated $2.77K sold.

Ares Financial Consulting first reported a position in PTCT in Q2 2026 and held it in 1 quarter. The position peaked at $2.77K in Q2 2026. 183 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Ares Financial Consulting reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 34 PTC Therapeutics shares in Q3 2026, an estimated $2.77K.
  • Ares Financial Consulting first reported a position in PTC Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's PTC Therapeutics position peaked at $2.77K in Q2 2026.
  • 183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.